Emma H. Doud
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Emma H. Doud has a total of 318 co-authors. Here are the top co-authors by number of shared publications:
- Amber L. Mosley
Indiana University School of Medicine
18 shared publications - Anthony J. Baucum
Department of Biochemistry, Molecular Biology, and Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA
5 shared publications - Whitney R. Smith-Kinnaman
Indiana University School of Medicine 7 Indianapolis, IN
5 shared publications - Sabrina Absalon
Indiana University School of Medicine
4 shared publications Amber L. Mosley
Indiana University
3 shared publications- Elizabeth Shinmay Yeh
Indiana University School of Medicine
3 shared publications
Latest Publications
- 4 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. Mutations in the small GTPase, KRAS, occur in over 90% of PDAC patients and drive signaling plasticity through phosphorylation cascades. Protein phosphatases are master regulators of signal transduction, yet the contribution of phosphatase dysregulation to mutant KRAS phenotypes is poorly understood. Protein phosphatase 2A (PP2A) inhibits KRAS effectors, placing this family of enzymes as key regulators of PDAC signaling. However, we previously demonstrated that pharmacological activation of PP2A elicits heterogeneous responses in PDAC cells, with some cell lines displaying augmented oncogenic signaling despite increased phosphatase activity. Here, we determined the impact of the specific PP2A subunit, B56a, on PDAC phenotypes using both genetic and pharmacological activation strategies in human PDAC cell lines and genetic mouse models. We demonstrate that B56a knockout reduces PDAC proliferation while exogenous expression exacerbates proliferative phenotypes. This increase in proliferation predominately occurs through epidermal growth factor receptor (EGFR), a critical signaling node associated with poor patient outcome. The activation of EGFR by PP2A-B56a is mediated through increased expression and processing of EGFR ligands, such as amphiregulin. In vivo, the genetic loss of Cip2a, an endogenous PP2A inhibitor, significantly increases EGFR activation and decreases overall survival. Finally, pharmacological activation of PP2A leads to increased EGFR signaling in tumors; however, EGFR inhibition mitigates this signaling and significantly decreases tumor growth compared to single-agent treatment alone. Together, these studies implicate a previously undescribed non-canonical role for PP2A-B56a in EGFR signaling that contributes to PDAC progression.
- 4 September 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
Activation of PP2A-B56a leads to aberrant EGFR signaling and proliferative phenotypes in PDAC
Pancreatic ductal adenocarcinoma (PDAC) stands to become the second most deadly cancer by 2030. Mutations in the small GTPase, KRAS, occur in over 90% of PDAC patients and drive signaling plasticity through phosphorylation cascades. Protein phosphatases are master regulators of signal transduction, yet the contribution of phosphatase dysregulation to mutant KRAS phenotypes is poorly understood. Protein phosphatase 2A (PP2A) inhibits KRAS effectors, placing this family of enzymes as key regulators of PDAC signaling. However, we previously demonstrated that pharmacological activation of PP2A elicits heterogeneous responses in PDAC cells, with some cell lines displaying augmented oncogenic signaling despite increased phosphatase activity. Here, we determined the impact of the specific PP2A subunit, B56a, on PDAC phenotypes using both genetic and pharmacological activation strategies in human PDAC cell lines and genetic mouse models. We demonstrate that B56a knockout reduces PDAC proliferation while exogenous expression exacerbates proliferative phenotypes. This increase in proliferation predominately occurs through epidermal growth factor receptor (EGFR), a critical signaling node associated with poor patient outcome. The activation of EGFR by PP2A-B56a is mediated through increased expression and processing of EGFR ligands, such as amphiregulin. In vivo, the genetic loss of Cip2a, an endogenous PP2A inhibitor, significantly increases EGFR activation and decreases overall survival. Finally, pharmacological activation of PP2A leads to increased EGFR signaling in tumors; however, EGFR inhibition mitigates this signaling and significantly decreases tumor growth compared to single-agent treatment alone. Together, these studies implicate a previously undescribed non-canonical role for PP2A-B56a in EGFR signaling that contributes to PDAC progression.
- Open Access
A CAMKK2-UBR4-19S Proteasome Axis Regulates Chondrocyte Proteostasis and SOX9 Stability
In early osteoarthritis (OA), chondrocytes undergo a shift from anabolic to catabolic states driven by a coordinated interplay between inflammation and the ubiquitin-proteasome system (UPS) that results in a rapid turnover of anabolic proteins, including the master chondrogenic transcription factor Sox9. However, the molecular mechanisms linking these processes remain unclear. Ca2+/calmodulin dependent protein kinase kinase 2 (CaMKK2) is elevated in OA cartilage, where it coordinates chondrocyte inflammatory responses. Here, we identify CaMKK2 as a novel regulator of chondrocyte UPS and Sox9 degradation. Pharmacological inhibition of CaMKK2 increased SOX9 in human OA cartilage, whereas its loss or inhibition preserved Sox9 following destabilization of the medial meniscus (DMM) surgery in mice. Expression of kinase-active, not kinase-inactive, CaMKK2 reduced Sox9 in human and mouse chondrocytes, indicating a role in Sox9 turnover. Proteomic analysis of CaMKK2 immunoprecipitates revealed the presence of ubiquitin E3 ligase Ubr4 and the 19S proteasome regulatory particle (RP). CaMKK2 kinase activity was dispensable for its interactions with Ubr4 and 19S RP subunits, and kinase-inactive CaMKK2 enriched higher molecular weight Sox9-ubiquitin conjugates and attenuated Sox9 degradation in chondrocytes. Mechanistically, CaMKK2 directly phosphorylated the 19S RP ATPase Psmc5 (Rpt6) on Ser136, and an intact kinase increased proteasome activity, which was diminished in Camkk2-/- chondrocytes. Our findings define CaMKK2 as a dual-function regulator of chondrocyte UPS with a scaffolding role to assemble Ubr4-19S RP complexes around polyubiquitinated proteins such as Sox9, and a catalytic role to enhance proteasome function, potentially through Psmc5 phosphorylation, thereby linking chondrocyte inflammatory signaling to Sox9 degradation and cartilage degeneration.
Open AccessA CAMKK2-UBR4-19S Proteasome Axis Regulates Chondrocyte Proteostasis and SOX9 Stability
In early osteoarthritis (OA), chondrocytes undergo a shift from anabolic to catabolic states driven by a coordinated interplay between inflammation and the ubiquitin-proteasome system (UPS) that results in a rapid turnover of anabolic proteins, including the master chondrogenic transcription factor Sox9. However, the molecular mechanisms linking these processes remain unclear. Ca2+/calmodulin dependent protein kinase kinase 2 (CaMKK2) is elevated in OA cartilage, where it coordinates chondrocyte inflammatory responses. Here, we identify CaMKK2 as a novel regulator of chondrocyte UPS and Sox9 degradation. Pharmacological inhibition of CaMKK2 increased SOX9 in human OA cartilage, whereas its loss or inhibition preserved Sox9 following destabilization of the medial meniscus (DMM) surgery in mice. Expression of kinase-active, not kinase-inactive, CaMKK2 reduced Sox9 in human and mouse chondrocytes, indicating a role in Sox9 turnover. Proteomic analysis of CaMKK2 immunoprecipitates revealed the presence of ubiquitin E3 ligase Ubr4 and the 19S proteasome regulatory particle (RP). CaMKK2 kinase activity was dispensable for its interactions with Ubr4 and 19S RP subunits, and kinase-inactive CaMKK2 enriched higher molecular weight Sox9-ubiquitin conjugates and attenuated Sox9 degradation in chondrocytes. Mechanistically, CaMKK2 directly phosphorylated the 19S RP ATPase Psmc5 (Rpt6) on Ser136, and an intact kinase increased proteasome activity, which was diminished in Camkk2-/- chondrocytes. Our findings define CaMKK2 as a dual-function regulator of chondrocyte UPS with a scaffolding role to assemble Ubr4-19S RP complexes around polyubiquitinated proteins such as Sox9, and a catalytic role to enhance proteasome function, potentially through Psmc5 phosphorylation, thereby linking chondrocyte inflammatory signaling to Sox9 degradation and cartilage degeneration.
- Open Access
EXOSC3 G191 Variants Trigger System-Wide Recalibration of RNA Processing Machinery
Pathogenic variants in EXOSC3, a noncatalytic subunit of the RNA exosome, cause pontocerebellar hypoplasia type 1B (PCH1B), yet substantial variability in disease severity is observed among individuals carrying different EXOSC3 alleles. The molecular mechanisms of RNA exosome dysfunction in individuals carrying EXOSC3 p.G191 variants remains unresolved. To address this, we generated CRISPR/Cas9-engineered human cell models harboring EXOSC3 p.G191 variants and performed integrated transcriptomic, proteomic, and computational structural analyses. EXOSC3 p.G191 variants produced extensive, allele- and dosage-dependent alterations in gene expression and splicing, with heterozygous variants causing broad but attenuated disruption relative to homozygous EXOSC3 G191D/G191D cells. All EXOSC3 G191 variants promoted increased skipping of exon 3 in EXOSC3 transcripts, generating a short isoform predicted to encode an unstable proteoform. Molecular dynamics and λ-dynamics simulations predicted substantial thermodynamic destabilization of all EXOSC3 G191 variant proteoforms, consistent with reduced protein abundance and thermal stability measured by global proteomics and PISA. At the protein complex level, EXOSC3 p.G191 variants were associated with coordinated decreases in all RNA exosome core subunits and the exonuclease EXOSC10, consistent with destabilization of RNA exosome assembly and orphan protein decay. In contrast, the catalytic exonuclease DIS3 and multiple independent RNA processing pathways were upregulated, indicating compensatory recalibration of RNA metabolism. Together, these findings link variant-induced alternative splicing, RNA exosome complex destabilization, and adaptive network responses to phenotypic variability in EXOSC3 p.G191-associated disease.
Open AccessEXOSC3 G191 Variants Trigger System-Wide Recalibration of RNA Processing Machinery
Pathogenic variants in EXOSC3, a noncatalytic subunit of the RNA exosome, cause pontocerebellar hypoplasia type 1B (PCH1B), yet substantial variability in disease severity is observed among individuals carrying different EXOSC3 alleles. The molecular mechanisms of RNA exosome dysfunction in individuals carrying EXOSC3 p.G191 variants remains unresolved. To address this, we generated CRISPR/Cas9-engineered human cell models harboring EXOSC3 p.G191 variants and performed integrated transcriptomic, proteomic, and computational structural analyses. EXOSC3 p.G191 variants produced extensive, allele- and dosage-dependent alterations in gene expression and splicing, with heterozygous variants causing broad but attenuated disruption relative to homozygous EXOSC3 G191D/G191D cells. All EXOSC3 G191 variants promoted increased skipping of exon 3 in EXOSC3 transcripts, generating a short isoform predicted to encode an unstable proteoform. Molecular dynamics and λ-dynamics simulations predicted substantial thermodynamic destabilization of all EXOSC3 G191 variant proteoforms, consistent with reduced protein abundance and thermal stability measured by global proteomics and PISA. At the protein complex level, EXOSC3 p.G191 variants were associated with coordinated decreases in all RNA exosome core subunits and the exonuclease EXOSC10, consistent with destabilization of RNA exosome assembly and orphan protein decay. In contrast, the catalytic exonuclease DIS3 and multiple independent RNA processing pathways were upregulated, indicating compensatory recalibration of RNA metabolism. Together, these findings link variant-induced alternative splicing, RNA exosome complex destabilization, and adaptive network responses to phenotypic variability in EXOSC3 p.G191-associated disease.
- Top Cited PapersOpen Access
Dual CDK4/6–PI3K/mTOR inhibition reinforces cytostatic programs and tumor control in preclinical models of primary and metastatic osteosarcoma
- Open Access
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
An essential adaptor for apicoplast fission and inheritance in malaria parasites
Blood-stage Plasmodium falciparum parasites rely on a non-photosynthetic plastid, the apicoplast, for survival, making it an attractive target for antimalarial intervention. Like the mitochondrion, the apicoplast cannot be generated de novo and must be inherited by daughter parasites during cell division. This inheritance relies on coordinated apicoplast positioning and fission, but the molecular mechanisms controlling these processes remain poorly understood. Here, we identify a previously uncharacterized P. falciparum protein (Pf3D7_0613600), which we name PfAnchor, as a key regulator of apicoplast fission. Using Ultrastructure Expansion Microscopy (U-ExM), we show that PfAnchor localizes to the apicoplast throughout the asexual blood-stage. Conditional depletion disrupts apicoplast fission, leading to incomplete cytokinesis and parasite death. Notably, loss of the apicoplast’s elongated branched structure via azithromycin treatment rescues these defects, underscoring Anchor’s specific role in apicoplast fission. Immunoprecipitation identified an interaction with the dynamin-like GTPase PfDyn2, a key mediator of both apicoplast and mitochondrial fission, establishing PfAnchor as the first apicoplast-specific dynamin adaptor protein. Our findings define PfAnchor as an essential factor for apicoplast fission and inheritance in P. falciparum blood-stage parasites, highlighting parasite-specific organelle division as a potential vulnerability for therapeutic intervention.
- 27 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1)
Open AccessAn essential adaptor for apicoplast fission and inheritance in malaria parasites
Blood-stage Plasmodium falciparum parasites rely on a non-photosynthetic plastid, the apicoplast, for survival, making it an attractive target for antimalarial intervention. Like the mitochondrion, the apicoplast cannot be generated de novo and must be inherited by daughter parasites during cell division. This inheritance relies on coordinated apicoplast positioning and fission, but the molecular mechanisms controlling these processes remain poorly understood. Here, we identify a previously uncharacterized P. falciparum protein (Pf3D7_0613600), which we name PfAnchor, as a key regulator of apicoplast fission. Using Ultrastructure Expansion Microscopy (U-ExM), we show that PfAnchor localizes to the apicoplast throughout the asexual blood-stage. Conditional depletion disrupts apicoplast fission, leading to incomplete cytokinesis and parasite death. Notably, loss of the apicoplast’s elongated branched structure via azithromycin treatment rescues these defects, underscoring Anchor’s specific role in apicoplast fission. Immunoprecipitation identified an interaction with the dynamin-like GTPase PfDyn2, a key mediator of both apicoplast and mitochondrial fission, establishing PfAnchor as the first apicoplast-specific dynamin adaptor protein. Our findings define PfAnchor as an essential factor for apicoplast fission and inheritance in P. falciparum blood-stage parasites, highlighting parasite-specific organelle division as a potential vulnerability for therapeutic intervention.
- Open Access
- 30 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0332969
Eliosin-an alternative product from the HmPKD1 locus is a component of endoplasmic reticulum mitochondria membrane contact sites
The human PKD1 gene locus region is the site that when mutated, causes 87% of the cases of human autosomal dominant polycystic kidney disease (ADPKD). This gene generates a full-length 14 kb message and encodes polycystin-1 (PC1). Informatic analysis of the PKD1 locus reveals 38 additional transcripts in the database, the most abundant cDNA is TESTI2047494 (GenBank ACC. No. DB056008) that maps to the 3’ region with active and open chromatin. This PKD1 locus region in human adult kidney cDNA probed by several sets of primers and sequencing produces an alternative transcript with a transcriptional start site in intron 40 that undergoes exon 42 skipping but aligns with exon 43−46 conventional splicing of the H mPKD1 gene. To assess the broader significance of this transcript, transcriptional characterization uncovered a highly similar murine renal alternative transcript suggesting a conserved functional role. The human alternative cDNA was analyzed for protein expression and only one of three reading frames led to a 47 kDa protein that is given the name Eliosin. Eliosin protein initiates from a non-canonical translation start site Leucine in exon 41 that generates 5 unique amino-terminal amino acids in a different frame from PKD1 . In 2D-gel analysis, Eliosin protein detected by anti-C terminal PC1 antibodies has a pI of 9.0 and the relative molecular weight was confirmed. Eliosin co-localizes with mitofusin-1, IP3R and dynamin related protein-1 (DRP1), proteins associated with ER mitochondria membrane contact sites (ERMCS). Eliosin observed in cotransfection studies with DRP1 support sequestration and/or competition mechanism at the ERMCS from classical interaction. Strikingly, exogenous Eliosin in immortalized ADPKD renal epithelial cells converts fragmented mitochondria populations to a filamentous shape. Our studies highlight the genomic complexity of the locus, a newly identified transcript and ERMCS protein, Eliosin with a role in mitochondria dynamics and potential impact in ADPKD progression.
- 30 October 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (10) , e0332969
Open AccessEliosin-an alternative product from the HmPKD1 locus is a component of endoplasmic reticulum mitochondria membrane contact sites
The human PKD1 gene locus region is the site that when mutated, causes 87% of the cases of human autosomal dominant polycystic kidney disease (ADPKD). This gene generates a full-length 14 kb message and encodes polycystin-1 (PC1). Informatic analysis of the PKD1 locus reveals 38 additional transcripts in the database, the most abundant cDNA is TESTI2047494 (GenBank ACC. No. DB056008) that maps to the 3’ region with active and open chromatin. This PKD1 locus region in human adult kidney cDNA probed by several sets of primers and sequencing produces an alternative transcript with a transcriptional start site in intron 40 that undergoes exon 42 skipping but aligns with exon 43−46 conventional splicing of the H mPKD1 gene. To assess the broader significance of this transcript, transcriptional characterization uncovered a highly similar murine renal alternative transcript suggesting a conserved functional role. The human alternative cDNA was analyzed for protein expression and only one of three reading frames led to a 47 kDa protein that is given the name Eliosin. Eliosin protein initiates from a non-canonical translation start site Leucine in exon 41 that generates 5 unique amino-terminal amino acids in a different frame from PKD1 . In 2D-gel analysis, Eliosin protein detected by anti-C terminal PC1 antibodies has a pI of 9.0 and the relative molecular weight was confirmed. Eliosin co-localizes with mitofusin-1, IP3R and dynamin related protein-1 (DRP1), proteins associated with ER mitochondria membrane contact sites (ERMCS). Eliosin observed in cotransfection studies with DRP1 support sequestration and/or competition mechanism at the ERMCS from classical interaction. Strikingly, exogenous Eliosin in immortalized ADPKD renal epithelial cells converts fragmented mitochondria populations to a filamentous shape. Our studies highlight the genomic complexity of the locus, a newly identified transcript and ERMCS protein, Eliosin with a role in mitochondria dynamics and potential impact in ADPKD progression.
- Open Access
Striatal spinophilin enhances D2R interaction with cytosolic proteins to mediate persistent D2R agonist-induced locomotor suppression
SUMMARY: Loss of dopamine neurons in Parkinson disease (PD) leads to motor deficits. Dopamine D2 receptor (D2R) agonists treat PD-associated motor deficits by acting on postsynaptic receptors located within the striatum that have been upregulated due dopamine loss. However, mechanisms that contribute to increased D2R activity in PD to enhance D2R function are poorly described. Spinophilin is a protein phosphatase 1 targeting protein that is expressed in postsynaptic dendritic spines and interacts with postsynaptic D2Rs. However, how spinophilin regulates D2R function is unknown. In the current study, we found that genetic knockout of spinophilin limited the suppression of locomotion caused by the D2R agonist, quinpirole. Mechanistically, we found that spinophilin is required for quinpirole-induced increases in the interaction of the D2R with intracellular proteins, suggesting spinophilin mediates agonist-induced D2R internalization. Therefore, our data support future studies targeting the spinophilin/D2R interaction to enhance the efficacy of current PD therapeutics.
Open AccessStriatal spinophilin enhances D2R interaction with cytosolic proteins to mediate persistent D2R agonist-induced locomotor suppression
SUMMARY: Loss of dopamine neurons in Parkinson disease (PD) leads to motor deficits. Dopamine D2 receptor (D2R) agonists treat PD-associated motor deficits by acting on postsynaptic receptors located within the striatum that have been upregulated due dopamine loss. However, mechanisms that contribute to increased D2R activity in PD to enhance D2R function are poorly described. Spinophilin is a protein phosphatase 1 targeting protein that is expressed in postsynaptic dendritic spines and interacts with postsynaptic D2Rs. However, how spinophilin regulates D2R function is unknown. In the current study, we found that genetic knockout of spinophilin limited the suppression of locomotion caused by the D2R agonist, quinpirole. Mechanistically, we found that spinophilin is required for quinpirole-induced increases in the interaction of the D2R with intracellular proteins, suggesting spinophilin mediates agonist-induced D2R internalization. Therefore, our data support future studies targeting the spinophilin/D2R interaction to enhance the efficacy of current PD therapeutics.
- Open Access
- 22 July 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2537118
Analytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer's disease, in murine biological matrices. This method addresses the challenges of quantifying biotherapeutics in multiple tissue types within preclinical animal models with complex genetic backgrounds, where traditional enzyme-linked immunosorbent assay (ELISA) methods may suffer from interference and limited sensitivity. The assay uses parallel reaction monitoring on a Lumos Tribrid Orbitrap mass spectrometer, coupled with an Evosep LC system, and AssayMap Bravo-based automated sample processing. Key features include protein A enrichment for improved sensitivity, optimized peptide selection based on sequence uniqueness and ionization response, and incorporation of stable isotope-labeled peptides for accurate quantification. Assay performance was evaluated for selectivity, repeatability, and stability. The fit-for-purpose assay was successfully applied to quantify chAdu in both mouse cortex and plasma samples obtained from a pilot pharmacokinetic study of a mouse model of amyloid plaque deposition. This targeted mass spectrometry workflow offers a robust and reproducible alternative to ELISA for preclinical biotherapeutic analysis, particularly when dealing with complex biological samples.
- 22 July 2025
- Published by Taylor & Francis in mAbs
- Vol. 17 (1) , 2537118
Open AccessAnalytical development and application of a targeted liquid chromatography-tandem mass spectrometry assay for chimeric aducanumab
A sensitive and specific liquid chromatography-tandem mass spectrometry assay was developed for the quantification of chimeric aducanumab (chAdu), a therapeutic antibody targeting pathological amyloid plaques in Alzheimer's disease, in murine biological matrices. This method addresses the challenges of quantifying biotherapeutics in multiple tissue types within preclinical animal models with complex genetic backgrounds, where traditional enzyme-linked immunosorbent assay (ELISA) methods may suffer from interference and limited sensitivity. The assay uses parallel reaction monitoring on a Lumos Tribrid Orbitrap mass spectrometer, coupled with an Evosep LC system, and AssayMap Bravo-based automated sample processing. Key features include protein A enrichment for improved sensitivity, optimized peptide selection based on sequence uniqueness and ionization response, and incorporation of stable isotope-labeled peptides for accurate quantification. Assay performance was evaluated for selectivity, repeatability, and stability. The fit-for-purpose assay was successfully applied to quantify chAdu in both mouse cortex and plasma samples obtained from a pilot pharmacokinetic study of a mouse model of amyloid plaque deposition. This targeted mass spectrometry workflow offers a robust and reproducible alternative to ELISA for preclinical biotherapeutic analysis, particularly when dealing with complex biological samples.
- Open Access
- 10 July 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (7)
Lipase M Is Essential for Skin Barrier Function in Mice
A functional skin barrier is essential for restricting water losses for terrestrial animals. The outermost layer of this barrier, the stratum corneum, consists of corneocytes (derived from terminally differentiated keratinocytes) coated with a protein‐rich envelope and a conjugated lipid‐rich envelope embedded in an organised hydrophobic intercellular lipid matrix. Gene mutations and environmental insults that affect corneocyte formation or the intercellular lipid matrix organisation cause skin barrier defects in mice and humans. Here we demonstrate mice homozygous for a loss‐of‐function mutation in the Lipm gene exhibit a diminished and discontinuous intercellular lipid matrix and a profound skin barrier defect associated with neonatal lethality. These findings suggest the protein encoded by the Lipm gene, lipase M (LIPM), is essential for skin barrier function by impacting intercellular lipid matrix organisation in the stratum corneum.
- 10 July 2025
- Published by Wiley in Experimental Dermatology
- Vol. 34 (7)
Open AccessLipase M Is Essential for Skin Barrier Function in Mice
A functional skin barrier is essential for restricting water losses for terrestrial animals. The outermost layer of this barrier, the stratum corneum, consists of corneocytes (derived from terminally differentiated keratinocytes) coated with a protein‐rich envelope and a conjugated lipid‐rich envelope embedded in an organised hydrophobic intercellular lipid matrix. Gene mutations and environmental insults that affect corneocyte formation or the intercellular lipid matrix organisation cause skin barrier defects in mice and humans. Here we demonstrate mice homozygous for a loss‐of‐function mutation in the Lipm gene exhibit a diminished and discontinuous intercellular lipid matrix and a profound skin barrier defect associated with neonatal lethality. These findings suggest the protein encoded by the Lipm gene, lipase M (LIPM), is essential for skin barrier function by impacting intercellular lipid matrix organisation in the stratum corneum.
- Open Access
- 20 June 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (12)
An engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations
Nonsense mutations that introduce premature termination codons (PTCs) into protein-coding genes are responsible for numerous genetic diseases; however, there are currently no effective treatment options for individuals affected by these mutations. One approach to combat nonsense-related diseases relies on the use of engineered suppressor transfer RNAs (sup-tRNAs) that facilitate translational stop codon readthrough, thereby restoring full-length protein synthesis. While several sup-tRNAs have shown promising results in preclinical models, many exhibit low PTC suppression efficiency, precluding their use as therapeutics. For example, glutamic acid (Glu) codons represent one of the most common sites for nonsense mutations, yet existing sup-tRNAs are ineffective at suppressing Glu-to-Stop mutations. To address this limitation, here we describe a rationally designed sup-tRNA (tRNAGluV13) with greatly improved ability to suppress PTCs occurring at Glu codons. We demonstrate that tRNAGluV13 efficiently restores protein synthesis from multiple nonsense-containing reporter genes, faithfully installing Glu in response to PTCs. Additionally, we demonstrate that tRNAGluV13 can functionally rescue pathogenic PTCs that cause hereditary breast and ovarian cancer syndrome and cystic fibrosis. The ability of tRNAGluV13 to effectively suppress one of the most common PTC mutations should greatly expand the potential of sup-tRNA-based therapeutics.
- 20 June 2025
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 53 (12)
Open AccessAn engineered glutamic acid tRNA for efficient suppression of pathogenic nonsense mutations
Nonsense mutations that introduce premature termination codons (PTCs) into protein-coding genes are responsible for numerous genetic diseases; however, there are currently no effective treatment options for individuals affected by these mutations. One approach to combat nonsense-related diseases relies on the use of engineered suppressor transfer RNAs (sup-tRNAs) that facilitate translational stop codon readthrough, thereby restoring full-length protein synthesis. While several sup-tRNAs have shown promising results in preclinical models, many exhibit low PTC suppression efficiency, precluding their use as therapeutics. For example, glutamic acid (Glu) codons represent one of the most common sites for nonsense mutations, yet existing sup-tRNAs are ineffective at suppressing Glu-to-Stop mutations. To address this limitation, here we describe a rationally designed sup-tRNA (tRNAGluV13) with greatly improved ability to suppress PTCs occurring at Glu codons. We demonstrate that tRNAGluV13 efficiently restores protein synthesis from multiple nonsense-containing reporter genes, faithfully installing Glu in response to PTCs. Additionally, we demonstrate that tRNAGluV13 can functionally rescue pathogenic PTCs that cause hereditary breast and ovarian cancer syndrome and cystic fibrosis. The ability of tRNAGluV13 to effectively suppress one of the most common PTC mutations should greatly expand the potential of sup-tRNA-based therapeutics.